SEBI probing possible insider trading in Ranbaxy ahead of deal with Sun Pharma

09 April, 2014

Securities and Exchange Board of India (SEBI) will ask the country’s stock exchanges for trading details on Ranbaxy Laboratories Ltd and Sun Pharmaceutical shares before the companies announced a merger on Monday, a senior source at the regulator said on Wednesday.

Ranbaxy shares had surged 24 percent in the three trading sessions leading up to the announcement on Monday that Sun Pharmaceutical had agreed to buy it for $3.2 billion.

“We have received multiple complaints. We will ask stock exchanges on details of buy and sell trades in both Ranbaxy and Sun shares,” said the source at SEBI.

He declined to be identified because he was not allowed to talk to media about the requests.

Exchange officials at National Stock Exchange of India Ltd and BSE Ltd were not immediately reachable.


Leave Your Comment
Andhra HC stays Sun Pharma-Ranbaxy deal till insider trading verdict

Andhra HC stays Sun Pharma-Ranbaxy deal till insider trading verdict

Anuradha Verma 3 years ago
The Andhra Pradesh High Court has issued orders to Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) to maintain interim status quo on the...
Sun Pharma-Ranbaxy deal gets BSE, NSE clearance

Sun Pharma-Ranbaxy deal gets BSE, NSE clearance

PTI 3 years ago
The USD 4-billion merger of Ranbaxy Labs with Sun Pharmaceutical has got clearance from the two leading stock exchanges — BSE and NSE. The ‘no-objection’...
Sun Pharma to buy Ranbaxy in $3.2B all-stock deal

Sun Pharma to buy Ranbaxy in $3.2B all-stock deal

TEAM VCC 3 years ago
Sun Pharmaceutical Industries Ltd, the country’s top drugmaker by market cap, is acquiring Ranbaxy Laboratories Ltd in an all-stock transaction, creating the world’s fifth-largest generics...
No Comments

SEBI probing possible insider trading in Ranbaxy ahead of deal with Sun Pharma

Powered by WordPress.com VIP